Investigating how sphingolipids affect non-small cell lung cancer driven by KRAS mutations
BCCMA: The Role of Sphingolipids in the Induction & Maintenance of Non-Small Cell Lung Cancer by Oncogenic KRAS
This study is looking at how certain fats in the body, called sphingolipids, might affect the growth of non-small cell lung cancer, especially when a specific gene is mutated, to find new ways to treat patients with this tough type of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Veterans Administration Hospital NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10951489 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of sphingolipids in the development and maintenance of non-small cell lung cancer (NSCLC), particularly in cases where the KRAS gene is mutated. The team aims to identify specific changes in sphingolipid metabolism that occur during the formation of cancer cells, which could lead to new therapeutic strategies. By using advanced techniques to analyze these metabolic pathways, the research seeks to translate findings from laboratory models to human NSCLC cases. Ultimately, the goal is to explore whether targeting sphingolipid pathways can provide new treatment options for patients with this aggressive form of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with KRAS mutations.
Not a fit: Patients with other types of lung cancer or those without KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve outcomes for patients with non-small cell lung cancer.
How similar studies have performed: While the role of sphingolipids in cancer is an emerging field, similar research has shown promise in understanding cancer metabolism and developing targeted therapies.
Where this research is happening
Richmond, United States
- VA Veterans Administration Hospital — Richmond, United States (Active)
Researchers
- Principal investigator: Chalfant, Charles E. — VA Veterans Administration Hospital
- Study coordinator: Chalfant, Charles E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.